Today’s Short Interest: Xoma Corporation (NASDAQ:XOMA) Stock Is Shorted Less

November 22, 2016 - By Louis Casey   ·   0 Comments

Today's Short Interest: Xoma Corporation (NASDAQ:XOMA) Stock Is Shorted Less

The stock of Xoma Corporation (NASDAQ:XOMA) registered a decrease of 1.6% in short interest. XOMA’s total short interest was 7.69M shares in November as published by FINRA. Its down 1.6% from 7.82M shares, reported previously. With 1.20 million shares average volume, it will take short sellers 6 days to cover their XOMA’s short positions. The short interest to Xoma Corporation’s float is 6.77%. The stock decreased 1.80% or $0.12 on November 21, hitting $6.53. XOMA Corporation (NASDAQ:XOMA) has declined 61.59% since April 20, 2016 and is downtrending. It has underperformed by 66.14% the S&P500.

Insitutional Activity: The institutional sentiment decreased to 0.47 in Q2 2016. Its down 0.12, from 0.59 in 2016Q1. The ratio is negative, as 22 funds sold all XOMA Corporation shares owned while 22 reduced positions. 16 funds bought stakes while 10 increased positions. They now own 20.41 million shares or 36.27% less from 32.03 million shares in 2016Q1.
Fmr Limited Liability Company last reported 1.53 million shares in the company. Alpine Partners Vi Ltd Liability Company holds 67,478 shares or 0.02% of its portfolio. Kcg Holding owns 127,081 shares or 0% of their US portfolio. Whittier Tru Company accumulated 0% or 33 shares. Group One Trading Limited Partnership has 53,913 shares for 0% of their US portfolio. Manufacturers Life Insur The holds 0% or 4,577 shares in its portfolio. Creative Planning reported 15,405 shares or 0% of all its holdings. Academy Mngmt Tx has invested 0% of its portfolio in XOMA Corporation (NASDAQ:XOMA). Highlander Capital Mngmt Ltd has 900 shares for 0% of their US portfolio. Renaissance Technology Ltd Liability Corp holds 0% of its portfolio in XOMA Corporation (NASDAQ:XOMA) for 461,220 shares. Tudor Invest Et Al, a Connecticut-based fund reported 30,730 shares. Huntington Savings Bank holds 0% or 624 shares in its portfolio. Blackrock Fund Advisors holds 0% or 19,642 shares in its portfolio. Lmr Prtnrs Ltd Liability Partnership has invested 0.01% of its portfolio in XOMA Corporation (NASDAQ:XOMA). Deutsche Natl Bank Ag owns 182,178 shares or 0% of their US portfolio.

Insider Transactions: Since November 1, 2016, the stock had 0 buys, and 1 insider sale for $788 net activity. Neal James R sold 150 shares worth $788.

XOMA Corporation (NASDAQ:XOMA) Ratings Coverage

Out of 5 analysts covering Xoma Limited (NASDAQ:XOMA), 0 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 0 are positive. $14 is the highest target while $1.50 is the lowest. The $7.75 average target is 18.68% above today’s ($6.53) stock price. Xoma Limited has been the topic of 9 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating given on Friday, September 4 by Zacks. Wedbush downgraded XOMA Corporation (NASDAQ:XOMA) on Monday, November 14 to “Neutral” rating. Wedbush maintained the stock with “Buy” rating in Wednesday, August 5 report. On Wednesday, July 22 the stock rating was downgraded by Ladenburg Thalmann to “Neutral”. The rating was downgraded by Zacks on Friday, August 28 to “Buy”. The stock of XOMA Corporation (NASDAQ:XOMA) has “Hold” rating given on Thursday, July 23 by Jefferies. The rating was downgraded by Piper Jaffray to “Neutral” on Wednesday, July 22.

XOMA Company Profile

XOMA Corporation, incorporated on December 31, 2011, is a development-stage biotechnology firm with a portfolio of therapeutic antibodies. The Firm focuses on the discovery and development of monoclonal antibody therapeutics. The Firm has over five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. The Company’s products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. The Company’s XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. The Company’s endocrine portfolio also includes a Phase II-ready product candidate, XOMA 213, targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH).

Another recent and important XOMA Corporation (NASDAQ:XOMA) news was published by which published an article titled: “Buy XOMA Corporation For Its Monoclonal Antibodies To Treat Congenital …” on July 24, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey

Readers Comments (0)

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News